Rhumbline Advisers Arbutus Biopharma Corp Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Rhumbline Advisers holds 177,874 shares of ABUS stock, worth $617,222. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177,874

Previous 185,067 3.89%

Holding current value

$617,222

Previous $571,000 19.79%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.12 - $4.56 $22,442 - $32,800	-7,193 Reduced 3.89%	177,874 $684,000
Q2 2024 Aug 01, 2024	BUY	$2.52 - $3.63 $36,809 - $53,023	14,607 Added 8.57%	185,067 $571,000
Q1 2024 May 09, 2024	BUY	$2.26 - $2.92 $13,189 - $17,041	5,836 Added 3.55%	170,460 $439,000
Q4 2023 Feb 08, 2024	SELL	$1.69 - $2.54 $6,097 - $9,164	-3,608 Reduced 2.14%	164,624 $411,000
Q3 2023 Nov 09, 2023	BUY	$1.9 - $2.27 $4,588 - $5,482	2,415 Added 1.46%	168,232 $341,000
Q2 2023 Aug 08, 2023	BUY	$2.24 - $3.06 $14,985 - $20,471	6,690 Added 4.2%	165,817 $381,000
Q1 2023 May 11, 2023	BUY	$2.23 - $3.1 $21,390 - $29,735	9,592 Added 6.41%	159,127 $482,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $12,787 - $19,080	6,695 Added 4.69%	149,535 $348,000
Q3 2022 Nov 10, 2022	BUY	$1.88 - $2.88 $14,882 - $22,798	7,916 Added 5.87%	142,840 $273,000
Q2 2022 Aug 11, 2022	BUY	$1.98 - $3.17 $61,669 - $98,732	31,146 Added 30.01%	134,924 $366,000
Q1 2022 May 12, 2022	BUY	$2.42 - $3.98 $32,048 - $52,707	13,243 Added 14.63%	103,778 $309,000
Q4 2021 Feb 10, 2022	BUY	$3.11 - $4.61 $220 - $327	71 Added 0.08%	90,535 $352,000
Q3 2021 Nov 12, 2021	BUY	$2.65 - $4.62 $6,746 - $11,762	2,546 Added 2.9%	90,464 $388,000
Q2 2021 Aug 05, 2021	BUY	$2.5 - $3.51 $219,795 - $308,592	87,918 New	87,918 $266,000
Q2 2019 Aug 14, 2019	SELL	$1.46 - $4.44 $70,951 - $215,770	-48,597 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$3.41 - $4.57 $1,483 - $1,987	-435 Reduced 0.89%	48,597 $174,000
Q4 2018 Jan 31, 2019	BUY	$3.5 - $9.66 $53,956 - $148,918	15,416 Added 45.86%	49,032 $188,000
Q3 2018 Nov 07, 2018	BUY	$7.85 - $12.35 $2,041 - $3,211	260 Added 0.78%	33,616 $318,000
Q2 2018 Aug 06, 2018	BUY	$5.0 - $7.35 $166,780 - $245,166	33,356 New	33,356 $243,000

Others Institutions Holding ABUS

# of Institutions

156

Shares Held

99.6M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $520M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Arbutus Biopharma Corp Transaction History